Overall, HRs (95 % CI) in this subset were as follows: hip fracture 0.90 (0.69,1.17), total fracture 0.95 (0.87,1.02),
MI 0.97 (0.80,1.17), CHD 1.01 (0.85,1.20), total heart disease 1.04 (0.94,1.16), stroke 0.83 (0.67,1.01), total cardiovascular disease 0.99 (0.90,1.08), colorectal cancer 1.32 (0.98, 1.79), breast cancer 1.09 (0.93,1.28), total invasive cancer 1.04 (0.94,1.15), and death 0.91 (0.79,1.04). None of these HRs differ significantly from unity, though for some outcomes, there is a significant HR difference between the personal supplements and no personal supplements subsets, including stroke (P = 0.04), colorectal cancer (P = 0.04), breast cancer (P = 0.01), and total invasive cancer (P = 0.03). Among women who were adherent to study pills, the overall HRs (95 % CIs) in the personal supplements DAPT supplier user subset were as follows: hip fracture 0.85 (0.58,1.24), total fracture 0.97 (0.87,1.07), MI 0.96 (0.74,1.26), CHD 1.00 (0.79,1.28), total heart disease 1.05 (0.91,1.21), stroke 0.81 (0.60,1.08), total cardiovascular disease 1.01 (0.89,1.14), colorectal cancer 1.17 (0.78,1.73), breast cancer 1.04 (0.85,1.29), total invasive cancer 1.02 (0.90,1.17), and death 0.91 (0.74,1.11). There was significant adherent HR variation between the personal supplements and no personal Apoptosis inhibitor supplements subsets
only for breast cancer (P = 0.03) and total invasive cancer (P = 0.03) in these adherence-adjusted analyses. Concerning https://www.selleckchem.com/products/EX-527.html urinary tract stones, as previously reported [1, 7] 449 women (0.35 %) in the group randomized to CaD and 381 women (0.30 %) in the placebo group developed urinary tract stones
during the trial intervention period, leading to an HR (95 % CI) of 1.17 (1.02, 1.34). Among adherent women, the HR (95 % CI) was 1.21 (0.98, 1.50). These analyses were repeated here, separately for the no personal supplements and personal supplements groups. In the no personal supplements subset, the HR (95 % CI) was 1.08 (0.88,1.32) based out on 199 women developing urinary tract stones in the active treatment group and 180 in the placebo group. The corresponding HR (95 % CI) in the personal supplements subset was 1.23 (1.01, 1.48) based on 239 and 197 women with stones in the active and placebo groups. The HRs did not differ significantly (P = 0.39) between the two subsets. Among adherent women, the HR (95 % CI) was 1.21 (0.87, 1.69) in the no personal supplements group and 1.19 (0.89, 1.58) in the personal supplements group, with no evidence (P = 0.87) for difference between the HRs for adherent women between the two subsets. Subset analyses by age group or by prior CVD history were generally similar to those for the overall cohorts for the various outcomes considered above and are not shown.